Literature DB >> 17668297

Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment.

Sreeja Jayant1, Jayant J Khandare, Yang Wang, Ajay P Singh, Nicholi Vorsa, Tamara Minko.   

Abstract

PURPOSE: To evaluate a novel targeted anticancer prodrug consisting of several copies of sialic acid (SA, targeting moiety), doxorubicin (DOX), citric acid (multifunctional spacer) and poly(ethylene glycol) (PEG, carrier).
METHODS: alpha, omega bis carboxyl PEG was covalently conjugated with multiple copies of SA and DOX through a citric acid spacer and characterized by proton nuclear magnetic resonance ((1)HNMR), matrix-assisted laser desorption/ionization-time of flight (MALDI/TOF), and high-performance liquid chromatography (HPLC). The molecular models of conjugates were established using ChemDraw software. Stability, spontaneous and esterase-stimulated drug release was analyzed by HPLC. Cellular internalization (fluorescence microscopy) and cytotoxicity [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay] of free DOX and prodrugs were evaluated.
RESULTS: (1)HNMR, MALDI/TOF, and HPLC showed the formation of the PEG prodrug conjugates. More than 40% of the drug was released from its conjugate in the presence of esterase enzyme, whereas the conjugate was stable at pH 7.4 in the absence of enzyme. Molecular modeling studies showed stable conformations of conjugates. The targeted prodrug conjugates with two copies of SA and DOX showed enhanced cytotoxicity when compared with non-targeted prodrugs and free DOX.
CONCLUSIONS: Targeting of the conjugate to cancer cells by SA with increased copies of targeting moiety and anticancer drug enhanced prodrug uptake by cancer cells and cytotoxicity of the prodrug.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17668297     DOI: 10.1007/s11095-007-9406-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

Review 1.  Modulation of xenobiotic metabolising enzymes by anticarcinogens -- focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis.

Authors:  Beatrice Pool-Zobel; Selvaraju Veeriah; Frank-D Böhmer
Journal:  Mutat Res       Date:  2005-08-03       Impact factor: 2.433

Review 2.  New generation of liposomal drugs for cancer.

Authors:  Tamara Minko; Refika I Pakunlu; Yang Wang; Jayant J Khandare; Maha Saad
Journal:  Anticancer Agents Med Chem       Date:  2006-11       Impact factor: 2.505

3.  Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel.

Authors:  Jayant J Khandare; Sreeja Jayant; Ajay Singh; Pooja Chandna; Yang Wang; Nicholi Vorsa; Tamara Minko
Journal:  Bioconjug Chem       Date:  2006 Nov-Dec       Impact factor: 4.774

4.  HPMA copolymer-bound doxorubicin induces apoptosis in human ovarian carcinoma cells by a Fas-independent pathway.

Authors:  Alexander Malugin; Pavla Kopecková; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2004 May-Jun       Impact factor: 4.939

5.  HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.

Authors:  T Minko; P Kopecková; V Pozharov; J Kopecek
Journal:  J Control Release       Date:  1998-07-31       Impact factor: 9.776

6.  Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides.

Authors:  S S Dharap; B Qiu; G C Williams; P Sinko; S Stein; T Minko
Journal:  J Control Release       Date:  2003-08-28       Impact factor: 9.776

Review 7.  Gangliosides as therapeutic targets for cancer.

Authors:  Pam Fredman; Kristina Hedberg; Thomas Brezicka
Journal:  BioDrugs       Date:  2003       Impact factor: 5.807

8.  Targeted proapoptotic LHRH-BH3 peptide.

Authors:  Sonia S Dharap; Tamara Minko
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

9.  Novel polymeric prodrug with multivalent components for cancer therapy.

Authors:  Jayant J Khandare; Pooja Chandna; Yang Wang; Vitaly P Pozharov; Tamara Minko
Journal:  J Pharmacol Exp Ther       Date:  2006-02-09       Impact factor: 4.030

10.  Characterization of covalent adriamycin-DNA adducts.

Authors:  S M Zeman; D R Phillips; D M Crothers
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

View more
  14 in total

1.  Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery.

Authors:  Oleh Taratula; Olga B Garbuzenko; Paul Kirkpatrick; Ipsit Pandya; Ronak Savla; Vitaly P Pozharov; Huixin He; Tamara Minko
Journal:  J Control Release       Date:  2009-06-28       Impact factor: 9.776

2.  A Sialylated-Bortezomib Prodrug Strategy Based on a Highly Expressed Selectin Target for the Treatment of Leukemia or Solid Tumors.

Authors:  Mingqi Liu; Xueying Tang; Junqiang Ding; Mengyang Liu; Bowen Zhao; Yihui Deng; Yanzhi Song
Journal:  Pharm Res       Date:  2019-11-04       Impact factor: 4.200

3.  Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers.

Authors:  Pooja Chandna; Jayant J Khandare; Elizabeth Ber; Lorna Rodriguez-Rodriguez; Tamara Minko
Journal:  Pharm Res       Date:  2010-08-11       Impact factor: 4.200

4.  Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance.

Authors:  Olga B Garbuzenko; Maha Saad; Vitaly P Pozharov; Kenneth R Reuhl; Gediminas Mainelis; Tamara Minko
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-24       Impact factor: 11.205

5.  An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis.

Authors:  Xianmin Meng; Mingqi Wang; Kaituo Zhang; Dezhi Sui; Meng Chen; Zihan Xu; Tiantian Guo; Xinrong Liu; Yihui Deng; Yanzhi Song
Journal:  AAPS PharmSciTech       Date:  2022-10-18       Impact factor: 4.026

6.  Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.

Authors:  Vatsal Shah; Oleh Taratula; Olga B Garbuzenko; Olena R Taratula; Lorna Rodriguez-Rodriguez; Tamara Minko
Journal:  Clin Cancer Res       Date:  2013-09-13       Impact factor: 12.531

7.  Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting.

Authors:  Mahesh L Patil; Min Zhang; Oleh Taratula; Olga B Garbuzenko; Huixin He; Tamara Minko
Journal:  Biomacromolecules       Date:  2009-02-09       Impact factor: 6.988

8.  Multifunctional triblock Nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing.

Authors:  Mahesh L Patil; Min Zhang; Tamara Minko
Journal:  ACS Nano       Date:  2011-02-15       Impact factor: 15.881

9.  Development of antimetastatic drugs by targeting tumor sialic acids.

Authors:  Da-Yong Lu; Ting-Ren Lu; Hong-Ying Wu
Journal:  Sci Pharm       Date:  2012-06-18

10.  Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles.

Authors:  Wei-liang Ye; Jiang-bo Du; Bang-le Zhang; Ren Na; Yan-feng Song; Qi-bing Mei; Ming-gao Zhao; Si-yuan Zhou
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.